ATE429926T1 - Verfahren zur hemmung der angiogenese unter verwendung von molekülen die die plasminbildung steigern oder die plasminaktivität verlängern - Google Patents

Verfahren zur hemmung der angiogenese unter verwendung von molekülen die die plasminbildung steigern oder die plasminaktivität verlängern

Info

Publication number
ATE429926T1
ATE429926T1 AT01912573T AT01912573T ATE429926T1 AT E429926 T1 ATE429926 T1 AT E429926T1 AT 01912573 T AT01912573 T AT 01912573T AT 01912573 T AT01912573 T AT 01912573T AT E429926 T1 ATE429926 T1 AT E429926T1
Authority
AT
Austria
Prior art keywords
plasmin
provisional matrix
formation
matrix
remodeling
Prior art date
Application number
AT01912573T
Other languages
English (en)
Inventor
Martijn Gebbink
Emile Voest
Original Assignee
Crossbeta Biosciences Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crossbeta Biosciences Bv filed Critical Crossbeta Biosciences Bv
Application granted granted Critical
Publication of ATE429926T1 publication Critical patent/ATE429926T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AT01912573T 2000-02-25 2001-02-26 Verfahren zur hemmung der angiogenese unter verwendung von molekülen die die plasminbildung steigern oder die plasminaktivität verlängern ATE429926T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00200664A EP1130031A1 (de) 2000-02-25 2000-02-25 Verfahren zur Hemmung der Angiogenese unter Verwendung von Molekülen die die Plasminbildung steigern oder die Plasminaktivität verlängern
PCT/NL2001/000155 WO2001062799A2 (en) 2000-02-25 2001-02-26 Method for inhibiting angiogenesis using molecules that enhance plasmin activity

Publications (1)

Publication Number Publication Date
ATE429926T1 true ATE429926T1 (de) 2009-05-15

Family

ID=8171096

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01912573T ATE429926T1 (de) 2000-02-25 2001-02-26 Verfahren zur hemmung der angiogenese unter verwendung von molekülen die die plasminbildung steigern oder die plasminaktivität verlängern

Country Status (7)

Country Link
US (2) US20030050245A1 (de)
EP (2) EP1130031A1 (de)
AT (1) ATE429926T1 (de)
AU (1) AU4126201A (de)
CA (1) CA2400823A1 (de)
DE (1) DE60138524D1 (de)
WO (1) WO2001062799A2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6689753B1 (en) * 1999-11-05 2004-02-10 Axonyx, Inc. β sheet breaker peptide analogs that inhibit β pleated sheet formation in amyloid β-peptide
EP1820806A1 (de) * 2006-02-16 2007-08-22 Crossbeta Biosciences B.V. Affinitätsbereiche
US20070003552A1 (en) * 2002-07-09 2007-01-04 Gebbink Martijn F B Cross-beta structure comprising amyloid binding proteins and methods for detection of the cross-beta structure, for modulating cross-beta structures fibril formation and for modulating cross-beta structure-mediated toxicity and method for interfering with blood coagulation
EP1380290A1 (de) * 2002-07-09 2004-01-14 Universitair Medisch Centrum Utrecht Cross-Beta-Strukturweg und seine therapeutische Relevanz
WO2004009773A2 (en) 2002-07-23 2004-01-29 Ludwig Institute For Cancer Research Methods and compositions for activating or inhibiting vegf-d and vegf-c
US20090202980A1 (en) * 2005-03-21 2009-08-13 Crossbeta Biosciences B.V. Cross-Beta Structure Comprising Amyloid Binding Proteins and Methods for Detection of the Cross-Beta Structure, for Modulating Cross-Beta Structures Fibril Formation and for Modulating Cross-Beta Structure-Mediated Toxicity and Method for Interfering With Blood Coagulation
EP1906995A2 (de) * 2005-07-13 2008-04-09 Crossbeta Biosciences B.V. Adjuvation durch kreuzstruktur
WO2007008073A2 (en) * 2005-07-13 2007-01-18 Crossbeta Biosciences B.V. METHODS FOR DETERMINING THE EFFECT OF A TREATMENT ON THE CROSS-ß STRUCTURE CONTENT OF A PROTEIN; SELECTION OF TREATMENTS AND USES THEREOF
US20070015133A1 (en) * 2005-07-13 2007-01-18 Umc Utrecht Holding B.V. Method for detecting and/or removing protein and/or peptide comprising a cross-beta structure from an aqueous solution comprising a protein
US8114832B2 (en) 2005-07-13 2012-02-14 Crossbeta Biosciences B.V. Method for detecting and/or removing a protein comprising a cross-beta structure from a pharmaceutical composition
AU2006267176A1 (en) 2005-07-13 2007-01-18 Crossbeta Biosciences B.V. Cross-beta structure binding compounds
EP2058001A1 (de) * 2007-11-08 2009-05-13 Crossbeta Biosciences B.V. Steigerung der Immunogenizität von Antigenen
EP2058000A1 (de) * 2007-11-08 2009-05-13 Crossbeta Biosciences B.V. Zur Aktivierung von T-Zellen fähige immunogene Zusammensetzung
TWI868333B (zh) * 2020-03-24 2025-01-01 大陸商深圳瑞健生命科學研究院有限公司 一種治療阿茲海默症的方法和藥物
KR20220156934A (ko) * 2020-03-24 2022-11-28 탈렌젠 인터내셔널 리미티드 잘못 접힌 단백질 및 이의 응집체 분해의 촉진 방법 및 약물
CA3182911A1 (en) 2020-05-11 2021-11-18 Talengen International Limited Method and drug for treating spinal muscular atrophy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3819923A1 (de) * 1988-06-11 1989-12-21 Behringwerke Ag Fibrin(ogen)derivate, verfahren zu ihrer herstellung und ihre verwendung
CA1335361C (en) * 1989-05-24 1995-04-25 Andrei Z. Budzynski Thrombus-targeted complexes of plasminogen activator and fibrin fragments
SE9101853D0 (sv) * 1991-06-17 1991-06-17 Jonas Wadstroem Improved tissue ashesive
CA2101614A1 (en) * 1992-07-30 1994-01-31 Shmuel Shaltiel Synthetic peptides derived from vitronectin and pharmaceutical compositions comprising them
DE4242736A1 (de) * 1992-12-17 1994-06-23 Behringwerke Ag Synthetische Peptide, Antikörper dagegen und ihre Verwendung
US5786324A (en) * 1994-03-24 1998-07-28 Regents Of The University Of Minnesota Synthetic peptides with bactericidal activity and endotoxin neutralizing activity for gram negative bacteria and methods for their use
AU709134B2 (en) * 1994-05-02 1999-08-19 E.R. Squibb & Sons, Inc. Recombinant fibrin chains, fibrin and fibrin-homologs
GB9815505D0 (en) * 1998-07-16 1998-09-16 Adprotech Plc Polypeptide derivatives

Also Published As

Publication number Publication date
EP1257582B1 (de) 2009-04-29
EP1130031A1 (de) 2001-09-05
US20060270599A1 (en) 2006-11-30
DE60138524D1 (de) 2009-06-10
US20030050245A1 (en) 2003-03-13
WO2001062799A2 (en) 2001-08-30
EP1257582A2 (de) 2002-11-20
WO2001062799A3 (en) 2002-04-04
AU4126201A (en) 2001-09-03
CA2400823A1 (en) 2001-08-30

Similar Documents

Publication Publication Date Title
ATE429926T1 (de) Verfahren zur hemmung der angiogenese unter verwendung von molekülen die die plasminbildung steigern oder die plasminaktivität verlängern
Delaissé et al. Proteinases in bone resorption: obvious and less obvious roles
Anand et al. A model for the formation and lysis of blood clots
FR15C0003I2 (fr) Production de muteines recombinantes du facteur de coagulation sanguine viii dans des lignees de cellules humaines
DK36991A (da) Vaevsplasminoaktivator-(t-pa)-variant med zymogene eller fibrinspecifikke eller plasmakoagel-specifikke egenskaber, fremgangsmaade til fremstilling deraf, dna-sekvens, som koder for varianten, replicerbar udtrykkelsesvektor for denne og vaertsceller transformeret med vektoren
Gailani et al. Structural and functional features of factor XI
DE60035274D1 (de) Vorrichtung zum spalten von mauerwerksblöcken mit vorsprüngen neben spaltmessern
DE69021849D1 (de) Verfahren zur Bestimmung des Spiegels von exogenen und endogenen Gerinnungsfaktoren und von Protein C.
ATE36457T1 (de) Verfahren zur inaktivierung von vermehrungsfaehigen krankheitserregern.
Masuda et al. cDNA cloning and characterization of vascular apoptosis-inducing protein 1
DE3780485D1 (de) Verfahren zur photometrischen bestimmung der protein c- und/oder protein s-aktivitaet.
ATE310092T1 (de) Verfahren zur herstellung von rekombinantem trypsin
Babarina et al. Role of the subchondral vascular system in endochondral ossification: endothelial cell-derived proteinases derepress late cartilage differentiation in vitro
ATE459091T1 (de) Methode zum entfernen einer mikroskopischen probe von einem substrat
DE60227335D1 (de) Kontinuierliches Verfahren zur Modifizierung von Stärke und Stärkederivate mittels Verzweigungsenzyme
ATA71292A (de) Verfahren zur spaltung von proteinen
Leonardi et al. Structural and biochemical characterisation of VaF1, a P-IIIa fibrinogenolytic metalloproteinase from Vipera ammodytes ammodytes venom
ATE416260T1 (de) Verfahren zur überwachung und modulierung von proteinfaltung
ATE501730T1 (de) Verfahren zur behandlung von psoriasis unter verwendung eines il-17d antagonisten
DE60318900D1 (de) Nukleinsäuren, polypeptide und verfahren zur modulierung der apoptose
ATE389010T1 (de) Verfahren zur herstellung von optisch aktiven pyridinethanol-derivaten
Zhou et al. A novel disintegrin, jerdonatin, inhibits platelet aggregation and sperm–egg binding
DE3784000D1 (de) Verfahren zur bestimmung von plasminogen.
DK1348761T3 (da) Marburg I mutant af faktor VII aktiverende protease (FSAP) som risikofaktor for arteriel thrombose
van Hinsbergh Role of Thrombin and Plasminogen Activators, Essential Proteases of the Coagulation and Fibrinolysis Cascades, in Fibrin Homeostasis and Vascular Cell Activation

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties